1036 related articles for article (PubMed ID: 18584413)
1. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.
Kapoor P; Suva LJ; Welch DR; Donahue HJ
J Cell Biochem; 2008 Jan; 103(1):30-41. PubMed ID: 17471510
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Expression of RANK-ligand in prostate cancer cell lines.
Penno H; Nilsson O; Brändström H; Winqvist O; Ljunggren O
Scand J Clin Lab Invest; 2009; 69(1):151-5. PubMed ID: 19058084
[TBL] [Abstract][Full Text] [Related]
6. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
7. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
Wang BL; Zheng F; Qiu MC
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
[TBL] [Abstract][Full Text] [Related]
8. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
9. Gu Ling Pian, a traditional Chinese medicine, regulates function and OPG/RANKL synthesis of osteoblasts via the p38 MAPK pathway.
Zhao Y; Li J; Liu Y; Yu KQ; Zhang J; Chen XG
J Pharm Pharmacol; 2007 Aug; 59(8):1167-73. PubMed ID: 17725861
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.
Rachner TD; Benad P; Rauner M; Goettsch C; Singh SK; Schoppet M; Hofbauer LC
J Cell Biochem; 2009 Sep; 108(1):106-16. PubMed ID: 19544400
[TBL] [Abstract][Full Text] [Related]
11. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
[TBL] [Abstract][Full Text] [Related]
12. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
13. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
14. [Effects of calcitonin on osteoblast cell proliferation and OPG/RANKL expression: experiment with mouse osteoblasts].
Tian QX; Huang GY; Zhou JL; Liu QH; DU XR
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1501-5. PubMed ID: 17785093
[TBL] [Abstract][Full Text] [Related]
15. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
Tat SK; Padrines M; Theoleyre S; Couillaud-Battaglia S; Heymann D; Redini F; Fortun Y
Bone; 2006 Oct; 39(4):706-15. PubMed ID: 16750945
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
17. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma.
Bhatia P; Sanders MM; Hansen MF
Clin Cancer Res; 2005 Jan; 11(1):162-5. PubMed ID: 15671541
[TBL] [Abstract][Full Text] [Related]
18. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
19. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
[TBL] [Abstract][Full Text] [Related]
20. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.
Nyambo R; Cross N; Lippitt J; Holen I; Bryden G; Hamdy FC; Eaton CL
J Bone Miner Res; 2004 Oct; 19(10):1712-21. PubMed ID: 15355567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]